

Damien Gruson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/472537/publications.pdf>

Version: 2024-02-01

105
papers

2,493
citations

304602

22
h-index

214721

47
g-index

109
all docs

109
docs citations

109
times ranked

3973
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. <i>Autoimmunity Reviews</i> , 2010, 9, 709-715.	2.5	469
2	Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. <i>Journal of Clinical Virology</i> , 2020, 128, 104413.	1.6	247
3	Interferences With Thyroid Function Immunoassays: Clinical Implications and Detection Algorithm. <i>Endocrine Reviews</i> , 2018, 39, 830-850.	8.9	164
4	Evaluation of Chilblains as a Manifestation of the COVID-19 Pandemic. <i>JAMA Dermatology</i> , 2020, 156, 998.	2.0	124
5	Increased plasma myostatin in heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 734-736.	2.9	87
6	Soluble ST2: A complex and diverse role in several diseases. <i>Clinica Chimica Acta</i> , 2020, 507, 75-87.	0.5	83
7	Data science, artificial intelligence, and machine learning: Opportunities for laboratory medicine and the value of positive regulation. <i>Clinical Biochemistry</i> , 2019, 69, 1-7.	0.8	79
8	Haploid Germ Cells Generated in Organotypic Culture of Testicular Tissue From Prepubertal Boys. <i>Frontiers in Physiology</i> , 2018, 9, 1413.	1.3	75
9	Circulating <sc>Activin A</sc> predicts survival in cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 768-777.	2.9	61
10	Key questions about the future of laboratory medicine in the next decade of the 21st century: A report from the IFCC-Emerging Technologies Division. <i>Clinica Chimica Acta</i> , 2019, 495, 570-589.	0.5	56
11	C-terminal FGF23 is a strong predictor of survival in systolic heart failure. <i>Peptides</i> , 2012, 37, 258-262.	1.2	54
12	Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. <i>EBioMedicine</i> , 2022, 77, 103893.	2.7	48
13	Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2014, 172, e250-e252.	0.8	46
14	Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 2494-2507.	1.4	43
15	Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID-19 patients. <i>Journal of Medical Virology</i> , 2021, 93, 1465-1477.	2.5	41
16	SFE/SFEDP adrenal insufficiency French consensus: Introduction and handbook. <i>Annales D'Endocrinologie</i> , 2018, 79, 1-22.	0.6	38
17	Sustainability in Healthcare: Perspectives and Reflections Regarding Laboratory Medicine. <i>Annals of Laboratory Medicine</i> , 2021, 41, 139-144.	1.2	32
18	Galectins testing: New promises for the diagnosis and risk stratification of chronic diseases?. <i>Clinical Biochemistry</i> , 2012, 45, 719-726.	0.8	31

#	ARTICLE	IF	CITATIONS
19	1,25-Dihydroxyvitamin D to PTH(1-84) Ratios Strongly Predict Cardiovascular Death in Heart Failure. PLoS ONE, 2015, 10, e0135427.	1.1	30
20	Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH). ESC Heart Failure, 2018, 5, 830-841.	1.4	29
21	Raised Plasma Urotensin II in Type 2 Diabetes Patients Is Associated With the Metabolic Syndrome Phenotype. Journal of Clinical Hypertension, 2010, 12, 653-660.	1.0	24
22	FGF23: Clinical usefulness and analytical evolution. Clinical Biochemistry, 2019, 66, 1-12.	0.8	23
23	Collaborative AI and Laboratory Medicine integration in precision cardiovascular medicine. Clinica Chimica Acta, 2020, 509, 67-71.	0.5	23
24	High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies. Clinical Biochemistry, 2020, 86, 23-27.	0.8	22
25	Biomarkers of inflammation and cardiac remodeling: the quest of relevant companions for the risk stratification of heart failure patients is still ongoing. Biochimica Medica, 2011, 21, 254-263.	1.2	22
26	The underestimated issue of non-reproducible cardiac troponin I and T results: case series and systematic review of the literature. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1201-1211.	1.4	21
27	Is There a Place for Bone Turnover Markers in the Assessment of Osteoporosis and its Treatment?. Rheumatic Disease Clinics of North America, 2011, 37, 365-386.	0.8	20
28	First trimester isolated maternal hypothyroxinaemia: adverse maternal metabolic profile and impact on the obstetrical outcome. Clinical Endocrinology, 2017, 86, 576-583.	1.2	20
29	Group 2: Adrenal insufficiency: screening methods and confirmation of diagnosis. Annales D'Endocrinologie, 2017, 78, 495-511.	0.6	20
30	Elevation of plasma oncostatin M in heart failure. Future Cardiology, 2017, 13, 219-227.	0.5	20
31	A biological profile for diagnosis and outcome of COVID-19 patients. Clinical Chemistry and Laboratory Medicine, 2020, 58, 2141-2150.	1.4	20
32	Biotin interference: evaluation of a new generation of electrochemiluminescent immunoassays for high-sensitive troponin T and thyroid-stimulating hormone testing. Clinical Chemistry and Laboratory Medicine, 2020, 58, 2037-2045.	1.4	18
33	Urotensin II and urocortin trigger the expression of myostatin, a negative regulator of cardiac growth, in cardiomyocytes. Peptides, 2012, 33, 351-353.	1.2	16
34	Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients. International Journal of Cardiology, 2015, 189, 185-187.	0.8	16
35	Sft-1 in heart failure: relation with disease severity and biomarkers. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 411-416.	0.6	16
36	Anti-streptavidin antibodies mimicking heterophilic antibodies in thyroid function tests. Clinical Chemistry and Laboratory Medicine, 2018, 56, e160-e163.	1.4	16

#	ARTICLE	IF	CITATIONS
37	Urocortin-induced cardiomyocytes hypertrophy is associated with regulation of the GSK-3 β pathway. <i>Heart and Vessels</i> , 2012, 27, 202-207.	0.5	14
38	Macro vitamin B12: an underestimated threat. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 408-415.	1.4	13
39	How well do laboratories adhere to recommended guidelines for dyslipidaemia management in Europe? The CARdiac MARker Guideline Uptake in Europe (CAMARGUE) study. <i>Clinica Chimica Acta</i> , 2020, 508, 267-272.	0.5	13
40	Interferences with cardiac biomarker assays: understanding the clinical impact. <i>European Heart Journal</i> , 2022, 43, 2286-2288.	1.0	12
41	Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* survey of Belgian specialists *THESIS: treatment of hypothyroidism in Europe by specialists: an international survey. <i>Thyroid Research</i> , 2022, 15, 3.	0.7	12
42	Accuracy of N-terminal pro-atrial natriuretic peptide in patients admitted to emergency department. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008, 68, 410-414.	0.6	10
43	Measurement of anti-Mullerian hormone: Performances of a new ultrasensitive immunoassay. <i>Clinical Biochemistry</i> , 2015, 48, 453-455.	0.8	10
44	Multiple biomarker strategy based on parathyroid hormone and natriuretic peptides testing for improved prognosis of chronic heart failure. <i>Peptides</i> , 2015, 64, 24-28.	1.2	10
45	Biotin interferences: Have we neglected the impact on serological markers?. <i>Clinica Chimica Acta</i> , 2020, 503, 107-112.	0.5	10
46	Impact of growth hormone (GH) treatment on circulating Nt-proBNP concentrations and on cardiac function in adult GH-deficient patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2012, 72, 387-394.	0.6	9
47	Aldosterone testing: evaluation of a novel automated immunoassay. <i>Biomarkers</i> , 2014, 19, 86-91.	0.9	9
48	Neutralization of biotin interference: preliminary evaluation of the VeraTest Biotin β , VeraPrep Biotin β and BioT-Filter [®] . <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, e130-e133.	1.4	9
49	Multimarker panel in patients admitted to emergency department: A comparison with reference methods. <i>Clinical Biochemistry</i> , 2009, 42, 185-188.	0.8	8
50	PTH and cardiovascular risk. <i>Annales D'Endocrinologie</i> , 2021, 82, 149-150.	0.6	8
51	Seroprevalence of SARS-CoV-2 infection in health care workers of a teaching hospital in Belgium: self-reported occupational and household risk factors for seropositivity. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 100, 115414.	0.8	8
52	Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection. <i>Scientific Reports</i> , 2022, 12, 2077.	1.6	8
53	Soluble ST2, the vitamin D/PTH axis and the heart: New interactions in the air?. <i>International Journal of Cardiology</i> , 2016, 212, 292-294.	0.8	7
54	Tracking Macroprolactin: Use of an Optimized Polyethylene Glycol Precipitation Method More Compatible with the Requirements and Processes of Automated Core Laboratories. <i>journal of applied laboratory medicine</i> , The, 2017, 1, 661-667.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Assessment of in vitro stability: a call for harmonization across studies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, e121-e124.	1.4	7
56	Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia. <i>Cancers</i> , 2020, 12, 3221.	1.7	7
57	How Well Do Laboratories Adhere to Recommended Guidelines for Cardiac Biomarkers Management in Europe? The CARdiac MARker Guideline Uptake in Europe (CAMARGUE) Study of the European Federation of Laboratory Medicine Task Group on Cardiac Markers. <i>Clinical Chemistry</i> , 2021, 67, 1144-1152.	1.5	7
58	Measurement of C-terminal cross-linking telopeptide of type I collagen: Evaluation of a new automated assay. <i>Clinical Biochemistry</i> , 2013, 46, 1778-1779.	0.8	6
59	Preanalytics of ammonia: stability, transport and temperature of centrifugation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, e65-e68.	1.4	6
60	Organisation and quality monitoring for point-of-care testing (POCT) in Belgium: proposal for an expansion of the legal framework for POCT into primary health care. <i>Acta Clinica Belgica</i> , 2022, 77, 329-336.	0.5	6
61	Update on current practice in laboratory medicine in respect of natriuretic peptide testing for heart failure diagnosis and management in Europe. The CARdiac MARker guideline Uptake in Europe (CARMAGUE) study. <i>Clinica Chimica Acta</i> , 2020, 511, 59-66.	0.5	6
62	Head-to-head comparison of the prohormone proBNP1â€“108 with BNP and Nt-proBNP in patients admitted to emergency department. <i>Clinical Biochemistry</i> , 2012, 45, 249-252.	0.8	5
63	Implementation of automated testing for 1,25-dihydroxyvitamin D: Return of experience from a core-laboratory. <i>Clinical Biochemistry</i> , 2016, 49, 298-301.	0.8	5
64	Systematic vitamin D supplementation and monitoring: improving outcomes in heart failure?. <i>European Journal of Heart Failure</i> , 2017, 19, 686-687.	2.9	5
65	Head to head comparison of intact and C-terminal fibroblast growth factor 23 in heart failure patients with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2017, 248, 270-273.	0.8	5
66	Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients. <i>Clinical Biochemistry</i> , 2018, 61, 47-49.	0.8	5
67	Biological variation and analytical goals of four thyroid function biomarkers in healthy European volunteers. <i>Clinical Endocrinology</i> , 2021, 94, 845-850.	1.2	5
68	Enhancing the value of the sFlt-1/PlGF ratio for the prediction of preeclampsia: Cost analysis from the Belgian healthcare payersâ€™ perspective. <i>Pregnancy Hypertension</i> , 2021, 26, 31-37.	0.6	5
69	Influence of secretory phenotype and preoperative preparation on surgical outcome in pheochromocytoma. <i>Endocrine Connections</i> , 2021, 10, 92-101.	0.8	5
70	A position paper of the EFLM Committee on Education and Training and Working Group on Distance Education Programmes/E-Learning: developing an e-learning platform for the education of stakeholders in laboratory medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 775-80.	1.4	4
71	Pre-eclampsia: overview on the role of biomarkers in 2016. <i>Annales De Biologie Clinique</i> , 2017, 75, 245-258.	0.2	4
72	Oxytocin testing and reproductive health: Status and clinical applications. <i>Clinical Biochemistry</i> , 2018, 62, 55-61.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Big Data, artificial intelligence and laboratory medicine: time for integration. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 1-3.	0.1	4
74	Digital Diagnostics and Mobile Health in Laboratory Medicine: An International Federation of Clinical Chemistry and Laboratory Medicineâ€™ Survey on Current Practice and Future Perspectives. <i>Journal of Applied Laboratory Medicine</i> , The, 2021, 6, 969-979.	0.6	4
75	Cross-reactivity of insulin analogs with the Diasorin Liaison Insulin assay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1081-1082.	1.4	3
76	Value of proBNP1â€™108 testing for the risk stratification of patients with systolic heart failure. <i>Peptides</i> , 2013, 50, 125-128.	1.2	3
77	Chromogranin-A Levels Measured with Automated Immunoassay. <i>International Journal of Biological Markers</i> , 2015, 30, 132-135.	0.7	3
78	Natriuretic peptides: degradation, circulating forms, dosages and new therapeutic approaches. <i>Annales De Biologie Clinique</i> , 2017, 75, 259-267.	0.2	3
79	Comment on â€™High doses of biotin can interfere with immunoassays that use biotin-strept(avidin) technologies: Implications for individuals with biotin-responsive inherited metabolic disordersâ€™. <i>Molecular Genetics and Metabolism Reports</i> , 2019, 21, 100506.	0.4	3
80	A rare case of tuberculosis-induced hypercalcemia. <i>Biochemia Medica</i> , 2020, 30, 471-474.	1.2	3
81	Anti-Mâ€™4 allergen testing: Evaluation of a novel method allowing more automation. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 681-5.	0.6	3
82	Artificial intelligence and thyroid disease management. <i>Biochemia Medica</i> , 2022, 32, 182-188.	1.2	3
83	Laboratory automation: how will you select the boarding assays?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, e167-9.	1.4	2
84	Football, concussions and biomarkers: Ready for more touchdowns?. <i>Clinical Biochemistry</i> , 2014, 47, 1345-1346.	0.8	2
85	Laboratory medicine and mobile health technologies at crossroads: Perspectives for the management of chronic diseases. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2016, 53, 352-357.	2.7	2
86	False-positive pregnancy test: beware of familial hCG syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e424-e425.	1.4	2
87	New Solutions for the Sample Transport and Results Delivery: A Digital Lab. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2018, 29, 210-214.	0.7	2
88	Short-term biological variation study of plasma hemophilia and thrombophilia parameters in a population of apparently healthy Caucasian adults. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1409-1415.	1.4	2
89	Diagnosing Destabilized Heart Failure in the Emergency Setting. <i>Molecular Diagnosis and Therapy</i> , 2011, 15, 327-340.	1.6	1
90	The IFCC Task Force for Young Scientists. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 753.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Continuous health monitoring: integrating biomarkers for the management of chronic diseases. <i>Biomarkers</i> , 2012, 17, 668-670.	0.9	1
92	First trimester placental growth factor and soluble fms-like tyrosine kinase 1 are significantly related to PAPP-A levels. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, e49-51.	1.4	1
93	A Challenging Case of Falsely Elevated Free Thyroid Hormones. <i>Journal of applied laboratory medicine</i> , The, 2020, 5, 406-411.	0.6	1
94	Performances of a novel chemiluminescence ABEL-based NT-proBNP immunoassay. <i>Acta Cardiologica</i> , 2022, 77, 176-179.	0.3	1
95	A colossal, enigmatic, and long-lasting high-sensitivity cardiac troponin T elevation. <i>Clinica Chimica Acta</i> , 2021, 520, 214-216.	0.5	1
96	Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: the potential benefits of monitoring FGF-23 levels?. <i>Annales D'Endocrinologie</i> , 2021, 83, 78-78.	0.6	1
97	Usefulness of a Non-Streptavidin Bead Technology to Overcome Biotin Interference: Proof of Principle with 25-OH Vitamin D, TSH, and FT4. <i>Journal of applied laboratory medicine</i> , The, 2021, 6, 1072-1077.	0.6	1
98	COVID-19: Armageddon before Light?. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2020, 31, 103-105.	0.7	1
99	Controlling Reliability, Interoperability and Security of Mobile Health Solutions. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2021, 32, 118-123.	0.7	1
100	Dosage du récepteur soluble sST2 : perspectives. <i>Revue Francophone Des Laboratoires</i> , 2017, 2017, 51-55.	0.0	0
101	Biomarkers in reproductive health. <i>Clinical Biochemistry</i> , 2018, 62, 1.	0.8	0
102	Big Data, inteligencia artificial y medicina de laboratorio: la hora de la integración. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 5-7.	0.1	0
103	Heart-type fatty acid binding protein is related to severity and established cardiac biomarkers of heart failure. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, .	0.1	0
104	La proteína de unión a los ácidos grasos cardíaca (HFABP) está relacionada con la gravedad de la insuficiencia cardíaca y sus biomarcadores cardíacos conocidos. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 545-549.	0.1	0
105	Testing for anti-Müllerian hormone: analytical performances and usability of a point-of-care assay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, .	1.4	0